In a report issued on July 18, Mani Foroohar from SVB Securities maintained a Buy rating on Decibel Therapeutics (DBTX – Research Report), with a price target of $14.00. The company’s shares closed last Tuesday at $4.67.
According to TipRanks.com, Foroohar is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -18.1% and a 38.3% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, 4D Molecular Therapeutics, and Recursion Pharmaceuticals.
Currently, the analyst consensus on Decibel Therapeutics is a Strong Buy with an average price target of $19.67.
Decibel Therapeutics’ market cap is currently $116.6M and has a P/E ratio of -2.12.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Decibel Therapeutics Inc is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments for hearing and balance disorders. It aims to restore and improve hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear.
Read More on DBTX: